SURF News and Press, Surface Oncology Inc. From 05/06/22

CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to five ...

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral pre...

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal ...

Surface Oncology (NASDAQ:SURF) said it began two phase 2 studies of SRF388 in liver and lung cancers. The company said a phase 2 trial is evaluating SRF388 in combination with Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) atezolizumab and bevacizumab against placebo plus atezolizumab and be...

Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer CAMBRIDGE, Ma...

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical and translational dat...

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Surface’s board of directors granted Theresa Bo...

Surface Oncology (NASDAQ:SURF) shares have climbed ~7% pre-market after the immuno-oncology firm achieved the $30M milestone payment with the first patient dosed by GlaxoSmithKline (NYSE:GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors. In late 2020, Surface sig...

Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...

CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been dosed by GlaxoSmithKline (GSK)...